Insmed Incorporated (NASDAQ:INSM) Given Average Rating of “Buy” by Analysts

Shares of Insmed Incorporated (NASDAQ:INSM) have been given a consensus rating of “Buy” by the sixteen ratings firms that are covering the stock, MarketBeat.com reports. Sixteen research analysts have rated the stock with a buy recommendation. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $94.00.

A number of brokerages have weighed in on INSM. Cantor Fitzgerald reissued an “overweight” rating on shares of Insmed in a report on Wednesday, February 19th. Guggenheim reaffirmed a “buy” rating and set a $101.00 price objective on shares of Insmed in a research note on Tuesday, February 25th. Truist Financial upped their price objective on shares of Insmed from $105.00 to $108.00 and gave the company a “buy” rating in a research note on Friday, February 21st. Royal Bank of Canada reaffirmed an “outperform” rating and set a $100.00 price objective on shares of Insmed in a research note on Wednesday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $90.00 price objective on shares of Insmed in a research note on Friday, February 21st.

Insmed Price Performance

Shares of NASDAQ INSM opened at $79.92 on Friday. Insmed has a twelve month low of $21.92 and a twelve month high of $84.91. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The company has a market capitalization of $14.47 billion, a price-to-earnings ratio of -14.30 and a beta of 1.28. The firm has a 50-day moving average of $77.43 and a two-hundred day moving average of $73.80.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The business had revenue of $104.44 million during the quarter, compared to analyst estimates of $102.31 million. As a group, analysts expect that Insmed will post -4.56 earnings per share for the current fiscal year.

Insider Buying and Selling at Insmed

In other news, CEO William Lewis sold 18,750 shares of the stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $69.84, for a total value of $1,309,500.00. Following the completion of the sale, the chief executive officer now directly owns 384,960 shares of the company’s stock, valued at approximately $26,885,606.40. This represents a 4.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Martina M.D. Flammer sold 6,172 shares of the stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $63.64, for a total value of $392,786.08. Following the completion of the sale, the insider now directly owns 101,549 shares of the company’s stock, valued at $6,462,578.36. This represents a 5.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 550,957 shares of company stock worth $42,992,528 over the last 90 days. Insiders own 4.60% of the company’s stock.

Institutional Investors Weigh In On Insmed

Hedge funds have recently modified their holdings of the business. Jennison Associates LLC lifted its position in Insmed by 0.6% in the fourth quarter. Jennison Associates LLC now owns 773,813 shares of the biopharmaceutical company’s stock worth $53,424,000 after purchasing an additional 4,560 shares during the period. Capital CS Group LLC bought a new position in Insmed in the fourth quarter worth $586,000. Orion Portfolio Solutions LLC lifted its position in Insmed by 48.5% in the third quarter. Orion Portfolio Solutions LLC now owns 28,087 shares of the biopharmaceutical company’s stock worth $2,050,000 after purchasing an additional 9,170 shares during the period. Ally Bridge Group NY LLC lifted its position in Insmed by 16.9% in the third quarter. Ally Bridge Group NY LLC now owns 150,833 shares of the biopharmaceutical company’s stock worth $11,011,000 after purchasing an additional 21,833 shares during the period. Finally, Vestal Point Capital LP lifted its position in Insmed by 113.3% in the third quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company’s stock worth $116,800,000 after purchasing an additional 850,000 shares during the period.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.